Product Program year 2025 Source: CMS Open Payments

Haegarda

Biological Immunology

NDC 63833-829-02

Open in the dashboard

General payments

$2,496,623

32,913 payments

Research payments

$1,272,578

242 payments

Through program year 2025, $2,496,623 in general payments and $1,272,578 in research payments were reported against Haegarda (Immunology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

11 rows
Year Kind Amount Payments
2025 General $137,092 3,692
2024 General $294,168 5,867
2023 General $254,154 5,131
2023 Research $6,200 2
2022 General $448,243 4,748
2022 Research $130,475 9
2021 General $438,809 5,568
2021 Research $384,738 42
2020 General $312,824 3,269
2020 Research $751,165 189
2019 General $611,334 4,638

Breakdown

Who paid General payments · program years 2019–2025
  1. CSL Behring $2,496,623 32,913 payments
Top recipients General payments · program year 2025
  1. Raffi Tachdjian Allergy & Immunology · Santa Monica, CA $20,964 15% · 13 payments
  2. Cristine Radojicic Allergy & Immunology · Durham, NC $7,292 5% · 6 payments
  3. William Lumry Dallas, TX $6,573 5% · 3 payments
  4. Priya Bansal Allergy & Immunology · Saint Charles, IL $6,534 5% · 9 payments
  5. Huamin Li Allergy · Wheaton, MD $6,511 5% · 13 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Allergy & Immunology $71,733 56% · 635 practitioners
  2. Allergy Allergy & Immunology $12,621 10% · 119 practitioners
  3. Nurse Practitioner, Family Nurse Practitioner $10,311 8% · 219 practitioners
  4. Physician Assistant $8,288 7% · 158 practitioners
  5. Nurse Practitioner $4,742 4% · 102 practitioners

The top 5 of 58 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $28,283 21% · 141 recipients
  2. New York $12,317 9% · 180 recipients
  3. Texas $12,022 9% · 137 recipients
  4. North Carolina $9,621 7% · 58 recipients
  5. Florida $8,847 6% · 173 recipients

The top 5 of 49 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

1,749

Prescriptions dispensed, refills included

Drug cost

$62,509,637

Paid at the pharmacy, in all

Prescribers

101

With 11 or more claims of it

Medicare Part D drugs matched to Haegarda, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Haegarda C1 Esterase Inhibitor Same name 101 1,749 $62,509,637

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Marc Riedl Allergy/ Immunology CA 47 $1,771,562 None on record
Joshua Jacobs Allergy/ Immunology CA 42 $1,925,416 $242
Carly Swint Physician Assistant CO 39 $836,749 $162
Robert Lazar Allergy/ Immunology MI 30 $705,367 $121
Sherif Taha Allergy/ Immunology NC 28 $644,000 $30

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
32,913 general · 242 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record